Abstract

Human implantation is a complex process requiring synchrony between a healthy embryo and a functionally competent or receptive endometrium. Diagnosis of endometrial receptivity (ER) has posed a challenge and so far, the most available tests have been subjective and lack accuracy and a predictive value. Microarray technology has allowed identification of the transcriptomic signature of the receptivity window of implantation (WOI). This technology has led to the development of a molecular diagnostic tool, the ER array (ERA) for diagnosis of ER. Use of this test in patients with recurrent implantation failure (RIF) has shown that the WOI is displaced in a most of these patients and the use of a personalized embryo transfer (pET) on the day designated by ERA improves reproductive performance. In this retrospective study, 74 patients with history of recurrent implantation failures who underwent Endometrial Receptivity Assay in ARC fertility centre, Saveetha medical college over a period of one year were analysed and 44 patients were receptive and 30 non receptive. Out of those 44 receptive patients 37(84.1%) were positive for clinical pregnancy and 7(23.3%) patients were negative for clinical pregnancy after performing pET. Among 30 of the non-receptive patients 7(15.9%) were found positive for clinical pregnancy and 23(76.7%) were found negative for clinical pregnancy. The p value was <0.001 which is statistically significant. Hence this study proves that doing ERA and performing Personal of clinical pregnancy rate and its outcome. Though larger studies are required to validate these results ERA has become a useful tool in our diagnostic armamentarium for ER.

Keywords: Endometrial receptivity; ERA; In-vitro fertilization; Recurrent implantation failure

Keywords: ER: Endometrial Receptivity; WOI: Window of Implantation; RIF: Recurrent Implantation Failure; PE: Phenotypes of Proliferative; ESE: Early Secretory; MSE: Mid‑Secretory; LSE: Late‑Secretory